Welcome to Multibagg AI
Log in to access personalized features
Portfolio
Alerts
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Get instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Discovery themes featuring this stockView Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Discovery themes featuring this stockAlembic Pharmaceuticals Ltd (APLLTD) is currently trading at 826.35 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Alembic Pharmaceuticals Limited is a vertically integrated Indian pharmaceutical company making and marketing generic formulations, APIs and branded generics in India while exporting to the U.S., Europe, ROW and country subsidiaries, with USFDA‑approved manufacturing and a significant ANDA pipeline (cumulative 270 filings and 212 cumulative final approvals). Q3 FY26 revenue grew 11% year‑on‑year to INR 1,876 crore, with gross margin of 72% and EBITDA before R&D at 25% of revenue; PAT before exceptional items rose 21% year‑on‑year to INR 168 crore, showing resilient operating leverage despite U.S. pricing pressure and higher R&D spend. R&D intensity is high—around 8–9% of revenue with quarterly R&D at INR 165 crore and full‑year guidance of INR 600–650 crore—supporting a strategy focused on complex injectables, ophthalmics, peptides and early‑entry ANDA opportunities including First‑to‑File and differentiated launches. Geographic diversification is advancing: U.S. grew modestly (6% in Q3) while EROW expanded 36% by region, API and Pfizer collaborations showing variable performance; management expects U.S. mid‑teens potential over coming years and aims to commercialize its first U.S. branded product (Pivya) in Q4 FY26.
Over the past 52 weeks, Alembic Pharmaceuticals Ltd has traded between a low of ₹635.30 and a high of ₹998.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Alembic Pharmaceuticals Ltd has a market capitalization of approximately 15,963.87. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Alembic Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 23.15 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 15,963.87 Cr, Alembic Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Alembic Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Alembic Pharmaceuticals Ltd is 23.15. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Revenue from operations rose 26% YoY to ₹2,149.77 crore, and consolidated net profit increased 12.1% YoY to ₹173.07 crore for the quarter ended June 30, 2026.
The post-results conference call is scheduled for Tuesday, August 4, 2026, at 5:30 PM IST, after the board meeting on the same day.
The post-results conference call is scheduled for Tuesday, August 4, 2026 at 5:30 PM IST, after the board meeting on the same day.
The USFDA completed a cGMP inspection at Alembic’s Karakhadi facility (Feb 9-18, 2026) and issued a Form 483 with two observations.
| Symbol | Watchlist | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
1383.05 | 17,006 Cr | 28.20 | 5.10 | 0.36 | 16.94 | 22.33 | 15.14 | ||
6776.85 | 16,963 Cr | 100.01 | 19.44 | 0.53 | 21.49 | 25.53 | 8.53 | ||
441.55 | 16,834 Cr | 287.62 | 4.30 | 0.00 | 5.05 | 5.47 | 1.02 | ||
1025.65 | 16,330 Cr | 46.47 | 2.30 | 0.49 | 5.62 | 6.41 | 2.26 | ||
810.50 | 15,964 Cr | 23.15 | 2.81 | 1.48 | 11.89 | 10.81 | 7.87 | ||
1510.00 | 15,762 Cr | 57.76 | 7.81 | 0.50 | 12.94 | 17.08 | 12.21 | ||
329.00 | 14,877 Cr | 28.54 | 4.92 | 0.27 | 13.82 | 17.37 | 13.50 | ||
| Median: 7 Co. | — | 1025.65 | 16,330 Cr | 46.47 | 4.92 | 0.49 | 12.94 | 17.08 | 8.53 |
Bearish
2
Neutral
8
Bullish
4
Bearish
2
Neutral
8
Bullish
36
Bearish
0
Neutral
0
Bullish
32
Bearish
2
Neutral
8
Bullish
4
Bearish
2
Neutral
8
Bullish
4
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Bearish
0
Neutral
0
Bullish
32
Alembic Pharmaceuticals Limited is a vertically integrated Indian pharmaceutical company making and marketing generic formulations, APIs and branded generics in India while exporting to the U.S., Europe, ROW and country subsidiaries, with USFDA‑approved manufacturing and a significant ANDA pipeline (cumulative 270 filings and 212 cumulative final approvals).
Q3 FY26 revenue grew 11% year‑on‑year to INR 1,876 crore, with gross margin of 72% and EBITDA before R&D at 25% of revenue; PAT before exceptional items rose 21% year‑on‑year to INR 168 crore, showing resilient operating leverage despite U.S. pricing pressure and higher R&D spend.
R&D intensity is high—around 8–9% of revenue with quarterly R&D at INR 165 crore and full‑year guidance of INR 600–650 crore—supporting a strategy focused on complex injectables, ophthalmics, peptides and early‑entry ANDA opportunities including First‑to‑File and differentiated launches.
Geographic diversification is advancing: U.S. grew modestly (6% in Q3) while EROW expanded 36% by region, API and Pfizer collaborations showing variable performance; management expects U.S. mid‑teens potential over coming years and aims to commercialize its first U.S. branded product (Pivya) in Q4 FY26.
Pharmaceuticals & Biotechnology
Pharmaceuticals
16,243 Cr
Low Risk
23.6
37.4
1.2
2.8
998.00
635.30
Sales CAGR
Profit CAGR
ROE
ROCE
